Iloperidone + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Feb 1, 2011 → Mar 1, 2015
NCT ID
NCT01291511About Iloperidone + Placebo
Iloperidone + Placebo is a phase 3 stage product being developed by Vanda Pharmaceuticals for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01291511. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07090161 | Phase 2 | Recruiting |
| NCT06961968 | Phase 3 | Recruiting |
| NCT01291511 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia